JP2019517564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517564A5 JP2019517564A5 JP2018564739A JP2018564739A JP2019517564A5 JP 2019517564 A5 JP2019517564 A5 JP 2019517564A5 JP 2018564739 A JP2018564739 A JP 2018564739A JP 2018564739 A JP2018564739 A JP 2018564739A JP 2019517564 A5 JP2019517564 A5 JP 2019517564A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- group
- silanol
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 229940079593 drug Drugs 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 25
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 stereoisomers Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000006850 spacer group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 150000005347 biaryls Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000005363 heterobiaryls Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229930126263 Maytansine Natural products 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical class N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 claims 1
- 239000012661 PARP inhibitor Substances 0.000 claims 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 1
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 claims 1
- 239000004189 Salinomycin Substances 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004419 alkynylene group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 1
- 229960001548 salinomycin Drugs 0.000 claims 1
- 235000019378 salinomycin Nutrition 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000004819 silanols Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022062287A JP7299372B2 (ja) | 2016-06-09 | 2022-04-04 | シラノールベースの治療用ペイロード |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347700P | 2016-06-09 | 2016-06-09 | |
| US62/347,700 | 2016-06-09 | ||
| US201662349274P | 2016-06-13 | 2016-06-13 | |
| US62/349,274 | 2016-06-13 | ||
| US201762477695P | 2017-03-28 | 2017-03-28 | |
| US62/477,695 | 2017-03-28 | ||
| PCT/US2017/036728 WO2017214491A1 (en) | 2016-06-09 | 2017-06-09 | Silanol based therapeutic payloads |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062287A Division JP7299372B2 (ja) | 2016-06-09 | 2022-04-04 | シラノールベースの治療用ペイロード |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517564A JP2019517564A (ja) | 2019-06-24 |
| JP2019517564A5 true JP2019517564A5 (enExample) | 2020-07-16 |
Family
ID=60578183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564739A Ceased JP2019517564A (ja) | 2016-06-09 | 2017-06-09 | シラノール系治療的ペイロード |
| JP2022062287A Active JP7299372B2 (ja) | 2016-06-09 | 2022-04-04 | シラノールベースの治療用ペイロード |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022062287A Active JP7299372B2 (ja) | 2016-06-09 | 2022-04-04 | シラノールベースの治療用ペイロード |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US10064880B2 (enExample) |
| EP (1) | EP3468500A4 (enExample) |
| JP (2) | JP2019517564A (enExample) |
| CN (1) | CN109475567A (enExample) |
| AU (1) | AU2017277949B2 (enExample) |
| CA (1) | CA3026651A1 (enExample) |
| WO (1) | WO2017214491A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6987641B2 (ja) | 2015-05-12 | 2022-01-05 | ブリンクバイオ インコーポレイテッド | シリコン系薬物複合体及びその使用方法 |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| CN110087680B (zh) | 2016-08-19 | 2024-03-19 | 百济神州有限公司 | 使用包含btk抑制剂的组合产品治疗癌症 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| CN109206610B (zh) | 2017-06-30 | 2020-06-30 | 北京键凯科技股份有限公司 | 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物 |
| WO2019001550A1 (zh) * | 2017-06-30 | 2019-01-03 | 北京键凯科技股份有限公司 | 一种适用于点击化学反应的多臂多爪聚乙二醇衍生物 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| BR112020018286A2 (pt) | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| WO2020079530A1 (en) * | 2018-10-18 | 2020-04-23 | 3M Innovative Properties Company | Silanol compositions and methods of use |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| EP3976112A1 (en) | 2019-06-03 | 2022-04-06 | Synaffix B.V. | Acetal-based cleavable linkers |
| WO2021018018A1 (en) * | 2019-07-26 | 2021-02-04 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
| EP4058464A1 (en) * | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| JP7807376B2 (ja) | 2020-01-13 | 2026-01-27 | シンアフィックス ビー．ブイ． | 付加環化を介して両側官能化された抗体 |
| WO2021144314A1 (en) | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| BR112022020521A2 (pt) | 2020-04-10 | 2023-03-07 | Rakuten Medical Inc | Compostos de corante ftalocianina, conjugados e métodos de uso dos mesmos |
| WO2021260232A1 (en) | 2020-06-26 | 2021-12-30 | Synaffix B.V. | Methods for the preparation of linker payload constructs |
| ES2963150T3 (es) | 2020-10-27 | 2024-03-25 | Elucida Oncology Inc | Procedimientos para funcionalizar nanopartículas |
| EP4274619A4 (en) * | 2021-01-08 | 2025-09-24 | Lycia Therapeutics Inc | BIFUNCTIONAL FOLATE RECEPTOR-BINDING COMPOUNDS |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4319817A4 (en) * | 2021-04-09 | 2026-05-27 | Rakuten Medical Inc | PHTHALOCYANINE-BASED COLOUR COMPOUNDS, CONJUGATES AND ASSOCIATED PROCESSES OF USE |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US20250127913A1 (en) * | 2021-06-24 | 2025-04-24 | Lycia Therapeutics, Inc. | Bifunctional folate receptor binding compounds |
| CN116531395B (zh) * | 2022-01-25 | 2024-11-05 | 沈阳药科大学 | 含青蒿素类衍生物的组合物及在制备治疗白血病药物中的应用 |
| US20250205353A1 (en) | 2022-03-23 | 2025-06-26 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing nectin-4 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| MX2024011519A (es) | 2022-03-23 | 2024-09-24 | Synaffix Bv | Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario. |
| CA3253220A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | ANTIBODIES CONJUGATED FOR TARGETING TUMORS EXPRESSING TROP-2 |
| WO2024044653A2 (en) * | 2022-08-24 | 2024-02-29 | Massachuesetts Institue Of Technology | Silyl carbamates and poly(silyl carbamates) and uses thereof |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839333T2 (de) | 1997-05-30 | 2009-07-09 | Shiseido Co. Ltd. | Zusammensetzung ein copolymer enthaltend das reaktive silyl-gruppen aufweist sowie verfahren zur verwendung |
| WO2004060977A1 (en) | 2002-12-30 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles |
| US7601332B2 (en) * | 2003-01-27 | 2009-10-13 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| JP2007511625A (ja) * | 2003-10-29 | 2007-05-10 | フイルメニツヒ ソシエテ アノニム | 無機物ナノ粒子に基づく香料送達系 |
| WO2006069096A1 (en) * | 2004-12-20 | 2006-06-29 | Pharmacyclics, Inc. | Silanol derivatives as inhibitors of histone deacetylase |
| AU2008282557A1 (en) | 2007-07-27 | 2009-02-05 | Ensemble Discovery Corporation | Detection assays and use thereof |
| US7687496B2 (en) | 2007-10-16 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
| WO2009051580A1 (en) * | 2007-10-16 | 2009-04-23 | Bionumerik Pharmaceuticals, Inc. | C7-substituted camptothecin analogs |
| WO2009076373A1 (en) | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| EP2279291B1 (en) | 2008-04-09 | 2019-07-03 | Cornell University | Coferons and methods of making and using them |
| AU2009337181A1 (en) | 2009-01-15 | 2011-08-04 | Board Of Regents Of The University Of Texas System | Porous structures with modified biodegradation kinetics |
| EP2443125B1 (en) * | 2009-06-17 | 2014-11-26 | Threshold Pharmaceuticals, Inc. | Camptothecin derivatives |
| EP2485678A4 (en) | 2009-10-07 | 2013-04-03 | Univ Cornell | Coferons and methods of making and using them |
| EP2646818A4 (en) * | 2010-11-30 | 2016-09-21 | Univ Illinois | SILICANANOPARTIKELKONJUGATE |
| WO2012092339A2 (en) | 2010-12-28 | 2012-07-05 | The Children's Hospital Of Philadelphia | The design of hydrolytically releasable prodrugs for sustained release nanoparticle formulations |
| US20140194383A1 (en) | 2011-04-07 | 2014-07-10 | Cornell University | Monomers capable of dimerizing in an aqueous solution, and methods of using same |
| US20140163229A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| US20140161729A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Cofluorons and methods of making and using them |
| WO2012139134A2 (en) | 2011-04-07 | 2012-10-11 | Coferon, Inc. | Methods of modulating oncogenic fusion proteins |
| WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
| WO2013033268A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bivalent bromodomain ligands, and methods of using same |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| WO2014124322A1 (en) * | 2013-02-08 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
| WO2014160305A1 (en) * | 2013-03-14 | 2014-10-02 | Albany Molecular Research, Inc. | Ligand-therapeutic agent conjugates and silicon-based linkers |
| US20150087043A1 (en) | 2013-04-11 | 2015-03-26 | Coferon, Inc | Monomers capable of multimerizing in an aqueous solution that employ bioorthogonal chemistries, and methods of using same |
| US20150080570A1 (en) | 2013-04-11 | 2015-03-19 | Coferon, Inc. | Alpha,beta-unsaturated monomers capable of multimerization in an aqueous solution, and methods of using same |
| JP6987641B2 (ja) | 2015-05-12 | 2022-01-05 | ブリンクバイオ インコーポレイテッド | シリコン系薬物複合体及びその使用方法 |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
-
2017
- 2017-06-09 CA CA3026651A patent/CA3026651A1/en active Pending
- 2017-06-09 AU AU2017277949A patent/AU2017277949B2/en not_active Ceased
- 2017-06-09 CN CN201780045309.4A patent/CN109475567A/zh active Pending
- 2017-06-09 EP EP17811071.4A patent/EP3468500A4/en not_active Withdrawn
- 2017-06-09 JP JP2018564739A patent/JP2019517564A/ja not_active Ceased
- 2017-06-09 WO PCT/US2017/036728 patent/WO2017214491A1/en not_active Ceased
-
2018
- 2018-03-15 US US15/922,264 patent/US10064880B2/en active Active
- 2018-07-17 US US16/037,447 patent/US10716801B2/en not_active Expired - Fee Related
- 2018-12-18 US US16/223,613 patent/US10293053B2/en active Active
-
2020
- 2020-06-29 US US16/914,977 patent/US11497757B2/en active Active
-
2022
- 2022-02-24 US US17/679,775 patent/US20220184104A1/en not_active Abandoned
- 2022-04-04 JP JP2022062287A patent/JP7299372B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2959419T3 (es) | Formulaciones secas por aspersión | |
| JP5931982B2 (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| US6403599B1 (en) | Corticotropin releasing factor antagonists | |
| JP4511792B2 (ja) | Ｃｏｘ−２阻害剤を含む再構成可能な非経口組成物 | |
| CA2717948C (en) | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes | |
| JP2017504611A (ja) | 組合せ医薬 | |
| HRP20161786T1 (hr) | Pirolidinil urea, pirolidinil tiourea i pirolidinil gvanidin spojevi kao inhibitori trka kinaze | |
| JP2018515438A5 (enExample) | ||
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2013544261A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2012515787A5 (enExample) | ||
| JP2020500866A5 (enExample) | ||
| CN107106685A (zh) | 协同澳瑞他汀组合 | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2018512403A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| RU2013132930A (ru) | Производное пиразола | |
| Shankaraiah et al. | Diverse targeted approaches to battle multidrug resistance in cancer | |
| AU2015342869A1 (en) | Apilimod for use in the treatment of renal cancer | |
| US20200306255A1 (en) | Compositions and methods for treating niemann pick c disease | |
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| RU2012155691A (ru) | Производные сложного аминоэфира алкалоида и их лекарственные композиции | |
| RU2012155690A (ru) | Алкалоидные производные сложных аминоэфиров и включающие их лекарственные композиции | |
| JP2008503466A5 (ja) | 勃起不全または尿失禁を治療または予防する化合物、組成物、および方法 |